Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Intravenous BIIB092 in Progressive Supranuclear Palsy
2016-002554-21Phase 2Completed
- Sponsor
- Biogen
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing BIIB092 with Placebo (2 arms). Primary endpoint: Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52. Started Apr 2017; status: completed.
02
Drugs
gosuranemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2016-002554-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002554-21.